Navigation Links
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007

iuretics; and -- the absence of treatment failure. Treatment failure was defined as: -- death; -- readmission to the hospital for heart failure within seven days of the first dose of KW-3902 or placebo; -- worsening of heart failure; or -- worsening renal function.

Patients treated with 30 milligrams of KW-3902 showed higher rates of treatment success and lower rates of treatment failure compared to the placebo group.

The pilot study also showed that 24-hours after treatment, self-reported marked or moderate improvement in dyspnea was observed in 66 percent of the patients who received the 30 milligram dose of KW-3902 as compared to 51 percent in the placebo group.

There were no statistical differences or trends in adverse events observed in the pilot study. The results of the study confirmed that 30 milligrams of KW-3902 is an appropriate dose for NovaCardia's two 600-patient pivotal Phase 3 trials, PROTECT 1 and PROTECT 2, which are currently enrolling participants in the United States, Canada, Europe, Israel and Russia.

KW-3902 is believed to block adenosine-mediated constriction of blood flow to the kidneys and inhibit reabsorption of salt and water by the kidney, thereby increasing urine volume and maintaining renal function in patients with CHF. As renal function deteriorates in patients with CHF, higher doses of diuretics are required in order to reduce fluid overload.

Multiple studies have demonstrated that renal dysfunction is a strong independent predictor of worse short- and long-term outcomes in patients with CHF. In the NovaCardia pilot study, the 30 milligram dose of KW-3902 also showed a positive effect on patients' renal function over time compared to placebo. Although KW-3902 was administered for only the first three days of the trial, an apparent dose response was seen in serum creatinine, a commonly used marker of worsening renal function, at day 14. The study showed no
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the global leader ... announced that Robert A. Ingram has retired from ... ardent champion for innovation in the lifesciences industry, and it ... board as we pursue our focused innovation strategy," said ... provided a valuable perspective to our board, drawing on his ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Results from Gene Identification Studies Presented at ASCO Support, ... ... REDWOOD CITY, Calif., May 31 Genomic Health,Inc. (Nasdaq: GHDX ... of two separate studies presented at the annual,meeting of the American ...
... from Phase III clinical trial --, CHICAGO, ... today announced the presentation of updated results from,a ... comparing,VELCADE and dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone ... of,19 percent in the VcD arm as induction ...
Cached Medicine Technology:Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 2Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 3Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 4Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Insurance Group, Inc. has re-branded their social media profiles to better connect with ... for consumers to communicate, find information, share insights and opinions. The Rally Insurance ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... (HealthDay News) -- The total economic cost of overweight and obesity ... cost in Canada is about $30 billion a year, a new ... States and Canada is the result of: increased need for medical ... of death ($49 billion); loss of productivity due to disability of ...
... whether interstitial brachytherapy has advantages compared to other therapy options ... provide proof in this respect. This is the result of ... in Health Care (IQWiG) on 11 January 2011. In this ... research already completed in 2007. However, it was shown that ...
... January 2011: With its spotlight theme of ,Controversial ... Society of Cardiology (ESC) Congress promises lively discussions and ... as the world,s premier cardiovascular conference and regularly attracts ... through its doors. It will be held this ...
... (MDCT) provides an efficient, effective way to analyze wounds from ... and in the March issue of Radiology . ... improve patient care and aid in both military and civilian ... D.O., M.P.H., from the Uniformed Services University in Bethesda, Md. ...
... that closely mirror some of the key properties of red ... of synthetic blood. The new discovery outlined in ... Proceedings of the National Academy of Sciences during ... to more effective treatments for life threatening medical conditions such ...
... , MONDAY, Jan. 10 (HealthDay News) -- The ... how to create a vaccine that can protect people against ... that people who were infected with the H1N1 virus and ... against a wide variety of flu strains. The virus ...
Cached Medicine News:Health News:Cost of Obesity Approaching $300 Billion a Year 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 4Health News:Countdown to Paris and ESC Congress 2011 2Health News:Countdown to Paris and ESC Congress 2011 3Health News:CT helps identify bullet trajectories 2Health News:UNC researchers inch closer to unlocking potential of synthetic blood 2Health News:UNC researchers inch closer to unlocking potential of synthetic blood 3Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: